
Allele-Specific Oligonucleotide (ASO) test for Cystic Fibrosis
Cystic Fibrosis
(CF) is
an
autosomal recessive disease,
characterized by accumulation
of
mucous
in
the lungs. The most common
allele
for CF contains a 3bp DNA
deletion,
called
508. In the pedigree, the birth of an affected
daughter (II-1) to two unaffected parents indicates that both
are heterozygotes. The question arises whether the two unaffected
siblings
are carriers for CF.
An oligonucleotide probe
is constructed with a sequence complementary to the exact DNA sequence of the allele with the
508
deletion, that is, an allele-specific
oligonucleotide (ASO). DNA is
obtained from all family members and spotted onto a Southern
hybridization
filter. The filter is probed with a radioactive ASO. Hybridization of the ASO to
the filter is indicated by a
spot on the autoradiogram,
which indicates the presence of
the
508
allele. The molecular
phenotypes of the heterozygous parents and the
affected
daughter are as predicted: each carries at least one
508
allele and therefore tests positive. The
unaffected
son
(II-2) tests "negative" for
the
508 allele and is therefore "homozygous normal", while his
unaffected sister (II-3) tests
positive for
508, and is therefore a "carrier" for CF.
Because the ASO method avoids
electrophoresis and size determinations, such tests are rapid
and suitable for large-scale population screens. The test as described
has two weaknesses as a diagnostic tool. First,
about
30% of CF cases in persons of
European ancestry are
due to
alternative alleles at this
locus not involving
508, and will not be detected with this specific test. Second, the hybridization test is subject to "false negatives",
for
example,
II-2 is a carrier but the ASO hybridization works weakly or
fails for technical
reasons. The test can then be improved by adding a parallel
ASO "control" test for the
"standard" allele:
